94 completed. 94 Phase 1, 21 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 94 | Completed 94 |
| Phase 2 | 21 | Completed 21 |
Follow Rhinitis, Allergic: new trials by email Literature Review of Rhinitis, Allergic trials Research Report on Rhinitis, Allergic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers AJU-R713, R713R - Bronchial Asthma, Perennial Allergic Rhinitis | Phase 1 | Completed | AJU Pharm Co., Ltd. | 62 | 2025-12-12 | 2026-09-18 |
| Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis PollenVax, Placebo - Rhinitis Allergic | Phase 1 | Completed | Kazakh National Agrarian University | 30 | 2025-11-22 | 2026-06-29 |
| Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects PA9159 nasal spray solution, 80 μg one day treatment, PA9159 nasal spray solution, 160 μg one day treatment, PA9159 nasal spray solution, 320 μg one day treatment - Allergic Rhinitis | Phase 1 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 36 | 2025-03-14 | 2026-01-15 |
| Serum sST2/ miR-223 as a Dual Biomarker for Disease Activity & Clinical Efficacy of SLIT in HDM-Induced Allergic Rhinitis Sublingual Immunotherapy (SLIT) containing HDM extracts - HDM-Induced Allergic Rhinitis | Phase 1 | Completed | Zagazig University | 54 | 2025-02-01 | 2026-02-27 |
| A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. GNR-127, 20 mcg, GNR-127, 40 mcg, GNR-127, 80 mcg - Rhinitis, Allergic, Seasonal | Phase 1 / Phase 2 | Completed | AO GENERIUM | 150 | 2024-10-07 | 2026-09-21 |
| Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis. INI-2004, Placebo - Allergic Rhinitis Due to Weed Pollen, Allergic Rhinitis | Phase 1 | Completed | Inimmune Corporation | 68 | 2023-07-04 | 2026-01-16 |
| Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray Azelastine Hydrochloride/ Fluticasone propionate nasal spray, 'DYMISTA' NASAL SPRAY - Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 56 | 2023-03-24 | 2023-12-28 |
| A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers Genolair, solution for subcutaneous administration, 150 mg, Genolair, lyophilisate for the preparation of solution for subcutaneous administration, Xolair®, solution for subcutaneous administration, 150 mg - Allergic Asthma | Phase 1 | Completed | AO GENERIUM | 180 | 2023-01-15 | 2024-07-10 |
| Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract Polvac Grass+Rye, Saline 0.9% - Rhinitis, Allergic, Seasonal, Rhinitis; Allergic, With Asthma | Phase 1 / Phase 2 | Completed | University of Zurich | 60 | 2022-02-10 | 2025-05-21 |
| Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects PA9159 nasal spray solution, 10 μg one day treatment, PA9159 nasal spray solution, 20 μg one day treatment, PA9159 nasal spray solution, 40 μg one day treatment - Allergic Rhinitis | Phase 1 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 60 | 2021-11-10 | 2022-01-19 |
| A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen Lu AG09222, Placebo - Allergic Rhinitis | Phase 1 | Completed | H. Lundbeck A/S | 30 | 2021-11-01 | 2022-10-27 |
| To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate) - Seasonal Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Humanis Saglık Anonim Sirketi | 48 | 2021-03-25 | 2023-12-13 |
| Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers CSPCHA115 100 mg; Matching placebo 100 mg, CSPCHA115 200 mg; Matching placebo 200 mg, CSPCHA115 400 mg; Matching placebo 400 mg - Asthma; Allergic Rhinitis | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 40 | 2019-12-12 | 2021-04-28 |
| Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults VRC-FLUNPF099-00-VP (H1ssF_3928) - Influenza Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 52 | 2019-04-01 | 2022-04-29 |
| Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis AD17002, Formulation Buffer - Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 48 | 2019-03-26 | 2025-09-16 |
| HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human HAL-MRE1 - Rhinitis, Allergic, Rhinoconjunctivitis, Allergic | Phase 1 | Completed | HAL Allergy | 45 | 2018-11-21 | 2019-08-06 |
| A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients MT-2990, Placebo - Seasonal Allergic Rhinitis | Phase 1 | Completed | Tanabe Pharma Corporation | 75 | 2018-07-17 | 2025-12-11 |
| Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass ALK Alutard 5-grasses and birch, ALK Diluent - Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Lars Olaf Cardell | 34 | 2018-05-15 | 2022-09-21 |
| Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis B244 suspension, Vehicle - Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen | Phase 1 / Phase 2 | Completed | AOBiome LLC | 71 | 2017-09-19 | 2022-11-25 |
| A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL Placebo comparator, Grass MATA MPL - Seasonal Allergic Rhinitis | Phase 1 | Completed | Allergy Therapeutics | 30 | 2017-01-16 | 2019-04-30 |
Showing 20 of 94. Sign in to see all of them.
Rhinitis, Allergic, Seasonal (31) · Rhinitis, Allergic, Perennial (15) · Asthma (13) · Hypersensitivity (12) · Rhinitis (4) · Dermatitis, Atopic (3) · Dust Mite Allergy (3) · Nasal Obstruction (3) · Sneezing (3) · Urticaria (3) · Immune System Diseases (2) · Pruritus (2) · Respiratory Hypersensitivity (2) · Respiratory Tract Diseases (2)
Hypersensitivity, Immediate (94) · Nose Diseases (94) · Otorhinolaryngologic Diseases (94) · Immune System Diseases (92) · Respiratory Hypersensitivity (92) · Respiratory Tract Diseases (92) · Rhinitis (90) · Hypersensitivity (82) · Bronchial Diseases (13) · Lung Diseases (13) · Lung Diseases, Obstructive (13) · Infections (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6)
Fluticasone (6) · azelastine (4) · Sodium Chloride (3) · Sublingual Immunotherapy (3) · AZD8848 (2) · Beclomethasone (2) · Mometasone Furoate (2) · Nasal Sprays (2) · Omalizumab (2) · Oxymetazoline (2) · Therapeutics (2) · bilastine (2) · Allergens (1) · BI 671800 (1) · Blood Specimen Collection (1)
GlaxoSmithKline (6) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Stallergenes Greer (5) · Pfizer (3) · AO GENERIUM (2) · Allergy Therapeutics (2) · Anhui Palo Alto Pharmaceuticals, Inc. (2) · AstraZeneca (2) · Faes Farma, S.A. (2) · Gachon University Gil Medical Center (2) · Gilead Sciences (2) · HAL Allergy (2) · Hanlim Pharm. Co., Ltd. (2) · Humanis Saglık Anonim Sirketi (2) · MEDA Pharma GmbH & Co. KG (2)
United States (24) · Germany (8) · South Korea (8) · United Kingdom (8) · Canada (5) · Australia (4) · Sweden (4) · Austria (3) · China (3) · Denmark (2) · Japan (2) · Netherlands (2) · Russia (2) · Switzerland (2) · Belgium (1)
Robert Wood, MD (4) · Christine Kolb (2) · Friedrich Horak, MD (2) · Oksana A. Markova, MD (2) · Alicia T Widge, M.D. (1) · Arthur C Ouwehand, PhD (1) · Cathy M Gelotte, PhD (1) · Darren Wilbraham, MBBS, DCPSA (1)
PMID 24184147, PMID 19001265, PMID 22464647, PMID 19680119, PMID 22726593, PMID 23374268, PMID 24035151, PMID 10831441, PMID 11069570, PMID 11297958, PMID 11468003, PMID 15379842, PMID 16553814, PMID 17083353, PMID 19647862, PMID 19717725, PMID 20921983, PMID 21642470, PMID 21725898, PMID 22393898, PMID 22621776, PMID 23181790, PMID 23725004, PMID 24105252, PMID 24261946, PMID 24439076, PMID 24934402, PMID 24986270, PMID 24990880, PMID 25149431, PMID 26044169, PMID 26342289, PMID 26553448, PMID 26706294, PMID 26843086, PMID 26915677, PMID 27231527, PMID 27253988, PMID 27357167, PMID 27677865, PMID 28911971, PMID 30391954, PMID 30881050, PMID 32679209, PMID 32926419, PMID 33099797, PMID 33647073, PMID 34088322, PMID 34187620, PMID 34429875
2009 (2), 2014 (1)